Pmv Pharmaceuticals Inc (PMVP) 13F Positioning & Ownership Changes (Q2 2026)

PMVP ranks #5562 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

64 institutions disclose a position in PMVP, but none treat it as a major bet — even BML Capital Management, LLC, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

Two Sigma Investments, LP has added to its PMVP position for two straight quarters, increasing it by $1.7M to reach $2.6M today.

ArrowMark Colorado Holdings LLC has trimmed its PMVP position for two straight quarters, cutting it by $1.2M while still holding $2.6M.

PMVP is down 5.3% today, and institutions have been net sellers of $2.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PMVP reported a net loss of $77.7M in its latest fiscal year.

• Not yet profitable — net loss of $77.7M in the latest fiscal year
• Net income declined year over year, from -$58.7M to -$77.7M
• Operating cash flow was negative, using $73.6M in cash
• Current ratio of 10.09x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range